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The most common mutation in cystic ﬁbrosis (CF), F508del, results in CFTR (CF
transmembrane conductance regulator) protein that is retained in the endoplasmic
reticulum and degraded via the proteasome. Previously, we have shown that
miglustat, an inhibitor of the a-1,2-glucosidase, corrects the trafﬁcking of F508del-
CFTR and hypothesized that by inhibiting the interaction of F508del-CFTR with
calnexin, miglustat prevents its retention and degradation (Norez et al., 2006). The
purpose of this study was to verify our hypothesis by i) determining the effect of
Small interfering RNA (SiRNA) glucosidase transfection on endogenous F508del-
CFTR trafﬁcking and ii) studing the effect of siRNA glucosidase transfection on
the interaction of F508del-CFTR with calnexin.
SiRNA glucosidase transfection was done on the CF-KM4 tracheal cell line to
inhibit expression of glucosidase. The level of glucosidase expression was veriﬁed
by biochemical technique and consequences on CFTR and ENaC activities were
assessed using single-cell ﬂuorescence imaging. The time-dependence effect of
transfection revealed a maximum transfection efﬁciency for 0.5 mg/ml of siRNA
at 72 hours. We demonstrated that transfection of siRNA glucosidase signiﬁcantly
knocked down glucosidase expression and resulted in a rescue of F508del-CFTR
activity at the plasma membrane and a decrease of ENaC activity.
In conclusion, this work shows that siRNA glucosidase rescues F508del-CFTR
activity at the plasma membrane and decreased ENaC activity. Next step will be to
verify if transfection with siRNA glucosidase inhibits the interaction of F508del-
CFTR with calnexin.
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The chloride channel mutated in cystic ﬁbrosis, CFTR, suffers from several major
defects that reduce its activity including a shortened surface half-life. Several PDZ
domain-containing proteins appear to regulate the trafﬁcking and activity of CFTR,
including Na+/H+ Exchanger-3 Regulatory Factors 1, 2 and 3 (NHERF1,2,3), which
increase CFTR-mediated chloride efﬂux whereas association with CFTR-associated
ligand (CAL) limits cell-surface levels of the disease-associated mutant DF508-
CFTR. RNAi-mediated knockdown of CAL increases CFTR surface expression
and chloride efﬂux by enhancing the channel’s stability at the apical surface,
demonstrating that CAL is a novel target for enhancing the CFTR half-life. However,
given the bi-directional promiscuity of the CAL:CFTR interaction, a more direct
test of this hypothesis requires inhibitors that can block the CAL:CFTR interaction
speciﬁcally and with high afﬁnity. Using ﬂuorescence polarization assays and
peptide array technology, we have identiﬁed a peptide inhibitor that is selective
for CAL over NHERF1, 2 and 3. In vitro pull-down assays and mass spectrometry
analysis indicate this peptide inhibitor is potent and selective for endogenous CAL.
Treatment of CFBE41o− airway epithelial cells with this peptide results in an
increase in DF508-CFTR activity. To identify pharmacological reagents that reca-
pitulate the effects of peptide inhibitors, we have now developed a high-throughput
screening platform utilizing ﬂuorescence detection and NMR heteronuclear single
quantum coherence (HSQC) spectroscopy.
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An imbalanced ion transport in several epithelia is a feature of CF, an inherited
disease as a consequence of mutations in the cftr gene. The cftr gene codes
for a Cl− channel. With some mutations in this gene, the balance between Cl−
secretion and Na+ absorption is disturbed in airways; Cl− secretion is impaired
while Na+ absorption is elevated. In this study we have examined the association
of ENaC subunits with mutated DF508-CFTR, the most common mutation in CF.
DF508 mutation prevents proper processing and targeting of CFTR to the plasma
membrane. When DF508 and ENaC subunits were coexpressed, we found that ENaC
subunits could be co-immunoprecipitated with DF508. Additionally, we evaluated
the DF508 and ENaC association by ﬂuorescence resonance energy transfer imaging
(FRET). FRET exploits the exquisite sensitivity of ﬂuorescence measurements to
detect molecular complexes with near angstrom resolution. FRET efﬁciencies were
not signiﬁcantly different from negative controls; these FRET results do not place
DF508 and ENaC in close proximity to each other. Even though our biochemical
ﬁndings are suggestive of an interaction (that could be direct or indirect) between the
mutated CFTR with ENaC subunits, these FRET data speak to the possibility that
the DF508 mutation might prevent a functional link between DF508 and ENaC.
This association most likely takes place in the ER; however, ENaC on the cell
surface may not be affected by the regulatory inﬂuence of mutated CFTR, and thus
exhibits an excessive activity.
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The aim of this study was to analyze the mechanism by which the new CFTR
V1108L mutation identiﬁed in a CAVD patient, disrupt CFTR function and
therefore cause male infertility. The V1108L mutation was generated by site directed
mutagenesis in a eukaryotic expression vector containing the wt CFTR cDNA. HEK
293 cell line was transiently transfected with the CFTR vector construct containing
the V1108L mutation, as well as with the pCMVCFTRNot6.2 (wt CFTR) and
pCMVCFTRNot6.2DF508 (F508del CFTR) plasmids as controls. To assess the
effect of the V1108L mutation in CFTR processing and intracellular trafﬁcking,
V1108L-CFTR protein was analyzed by Western blotting and immunoﬂuorescence,
respectively. Our results suggested that V1108L mutation, leads to a CFTR protein
that is correctly processed and trafﬁcked to the cell surface and hence is likely
not to cause a drastic defect on CFTR biosynthetic pathway. However, as indicated
by densitometric analysis, the ratio of mature fully-glycosylated to immature core-
glycosylated bands detected for V1108L-CFTR appeared to be lower than those
obtained for wt CFTR, indicating that V1108L mutation may cause dysfunction of
CFTR by decreasing the total amount of mature protein that reach the cell surface.
As the relative impact of CFTR genotype on clinical phenotype is organ speciﬁc, the
reduced amount of V1108L-CFTR that reach the cell, though small, as suggested by
the immunoﬂuorescence analysis, may affect the development of the vas deferens,
leading the CAVD phenotype observed in our patient. Thus, based in our results
and bioinformatic tools, the V1108L mutation may be classiﬁed as being associated
with CFTR-related disorders.
